MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-27-2026
Utah Medical Products Income Statement 2011-2026 | UTMD
Annual Income Statement Utah Medical Products
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
199 M | 216 M | 247 M | 338 M | 328 M | 306 M | 376 M | 349 M | 342 M | 232 M | 213 M | 214 M | 202 M | 151 M | 109 M |
Shares |
3.24 M | 3.5 M | 3.63 M | 3.64 M | 3.65 M | 3.66 M | 3.74 M | 3.72 M | 3.72 M | 3.77 M | 3.77 M | 3.77 M | 3.77 M | 3.71 M | 3.64 M |
Historical Prices |
61.5 | 61.5 | 68.1 | 92.9 | 90 | 83.6 | 85.5 | 82 | 84.7 | 58.2 | 54.8 | 53.7 | 48.7 | 35.9 | 25.6 |
Net Income |
2.56 M | 2.9 M | 4.29 M | 4.56 M | 4.13 M | 3.41 M | 14.7 M | 18.6 M | 8.5 M | 12.1 M | 11.8 M | 11.4 M | 11.4 M | 10.2 M | 7.41 M |
Revenue |
9.04 M | 9.16 M | 12.3 M | 13.6 M | 12.9 M | 12 M | 46.9 M | 42 M | 41.4 M | 39.3 M | 40.2 M | 41.3 M | 40.5 M | 41.6 M | 37.9 M |
Cost of Revenue |
16.5 M | 16.8 M | 20.2 M | 20.1 M | 18.1 M | 16.6 M | 17.4 M | 15.7 M | 15 M | 15.6 M | - | - | - | - | - |
Gross Profit |
5.26 M | 5.32 M | 7.1 M | 8.33 M | 8.11 M | 7.26 M | 29.5 M | 26.3 M | 26.4 M | 23.7 M | 24.2 M | 25 M | 24.3 M | 25.3 M | 22.4 M |
Operating Income |
11.4 M | 13.6 M | 16.8 M | 19.8 M | 18.9 M | 13.7 M | 17.6 M | 18.7 M | 19 M | 16.2 M | 15.7 M | 16.2 M | 14.8 M | 15.2 M | 11.8 M |
Interest Expense |
-120 K | -174 K | 256 K | 188 K | - | - | -8 K | 437 K | -32 K | 132 K | 65 K | 289 K | 438 K | 652 K | 859 K |
EBITDA |
12.2 M | 14.3 M | 17.4 M | 20.4 M | 19.5 M | 14.4 M | 24.5 M | 21.7 M | 21.8 M | 19 M | 18.8 M | 19.6 M | 18 M | 18.5 M | 14.6 M |
Operating Expenses |
- | - | - | - | - | - | 11.8 M | 7.61 M | 7.38 M | 7.5 M | 8.53 M | 8.78 M | 9.44 M | 10.1 M | 10.6 M |
General and Administrative Expenses |
7.88 M | 7.84 M | 11 M | 10.4 M | 10.1 M | 9.8 M | 9.61 M | 5.45 M | 5.39 M | 5.36 M | 5.85 M | 6.11 M | 6.16 M | 6.84 M | 7.22 M |
All numbers in USD currency
Quarterly Income Statement Utah Medical Products
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
3.21 M | 3.25 M | 3.31 M | 3.34 M | 3.48 M | 3.53 M | 3.62 M | 3.63 M | 3.63 M | 3.63 M | 3.63 M | 3.63 M | 3.62 M | 3.64 M | 3.66 M | 3.66 M | 3.65 M | 3.65 M | 3.64 M | 3.64 M | 3.64 M | 3.64 M | 3.71 M | 3.72 M | 3.72 M | 3.72 M | 3.72 M | 3.72 K | 3.73 M | 3.73 M | 3.72 M | 3.72 K | 3.72 M | 3.72 M | 3.71 M | 3.71 M | 3.76 M | 3.76 M | 3.75 M | 3.75 M | 3.75 M | 3.76 M | 3.75 M | 3.75 M | 3.74 M | 3.75 M | 3.75 M | 3.74 M | 3.74 M | 3.72 M | 3.71 M | 3.7 M | 3.69 M | 3.68 M | 3.65 M | 3.64 M | 3.64 M | 3.63 M | 3.62 M |
Net Income |
2.63 M | 3.05 M | 3.04 M | - | 3.56 M | 3.45 M | 3.96 M | - | 3.94 M | 4.2 M | 4.21 M | - | 4.28 M | 4.1 M | 3.53 M | 4.13 M | 4.21 M | 3.43 M | 3.02 M | 3.41 M | 2.93 M | 1.31 M | 3.14 M | 4.36 M | 3.7 M | 3.52 M | 3.14 M | 3.39 M | 6.76 M | 4.31 M | 4.09 M | -2.52 M | 3.62 M | 3.87 M | 3.54 M | - | 2.94 M | 3.26 M | 3.22 M | - | 3.05 M | 2.92 M | 2.67 M | - | 2.82 M | 2.83 M | 2.72 M | - | 2.57 M | 2.63 M | 2.74 M | - | 2.72 M | 2.4 M | 2.79 M | - | 2.24 M | 1.98 M | 1.34 M |
Revenue |
9.81 M | 9.95 M | 9.71 M | - | 10 M | 10.4 M | 11.3 M | - | 12.5 M | 12.9 M | 12.5 M | - | 13 M | 13.4 M | 12.3 M | 12.9 M | 12.6 M | 12.6 M | 11 M | 12 M | 10.5 M | 8.79 M | 10.9 M | 11.8 M | 12.5 M | 11.8 M | 10.7 M | 9.76 M | 10.4 M | 11 M | 10.9 M | 10.2 M | 10.1 M | 10.8 M | 10.3 M | - | 9.66 M | 10.5 M | 10.3 M | - | 9.94 M | 10.4 M | 10.2 M | - | 10.7 M | 10.5 M | 9.83 M | - | 10 M | 10 M | 10.4 M | - | 10.5 M | 10 M | 11.2 M | - | 10.8 M | 10.4 M | 6.79 M |
Cost of Revenue |
4.21 M | 4.36 M | 4.17 M | - | 4.2 M | 4.15 M | 4.57 M | - | 5.15 M | 5.13 M | 4.68 M | - | 4.77 M | 5.28 M | 4.79 M | - | 4.5 M | 4.82 M | 4.02 M | - | 3.98 M | 3.84 M | 4.07 M | - | 5.12 M | 4.35 M | 3.96 M | - | 4.1 M | 3.98 M | 3.96 M | - | 3.63 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
5.6 M | 5.6 M | 5.54 M | - | 5.8 M | 6.25 M | 6.77 M | - | 7.36 M | 7.74 M | 7.84 M | - | 8.19 M | 8.15 M | 7.53 M | 8.11 M | 8.07 M | 7.78 M | 6.95 M | 7.26 M | 6.5 M | 4.95 M | 6.84 M | 7.81 M | 7.38 M | 7.5 M | 6.77 M | 6.11 M | 6.29 M | 6.98 M | 6.92 M | 6.47 M | 6.5 M | 6.89 M | 6.54 M | - | 5.78 M | 6.25 M | 6.22 M | - | 6.08 M | 6.1 M | 6.11 M | - | 6.2 M | 6.35 M | 6.05 M | - | 5.95 M | 6.05 M | 6.28 M | - | 6.48 M | 6.07 M | 6.74 M | - | 6.52 M | 6.26 M | 3.71 M |
Operating Income |
2.61 M | 3.2 M | 3.15 M | - | 3.34 M | 3.44 M | 3.88 M | - | 3.97 M | 4.42 M | 4.44 M | - | 5.14 M | 5.06 M | 4.52 M | - | 5.1 M | 4.76 M | 3.89 M | - | 3.59 M | 1.98 M | 3.86 M | - | 4.37 M | 4.48 M | 4.1 M | - | 4.4 M | 5.06 M | 4.97 M | - | 4.68 M | 5.03 M | 4.72 M | - | 3.94 M | 4.32 M | 4.31 M | - | 4 M | 3.97 M | 3.88 M | - | 4 M | 4.06 M | 3.84 M | - | 3.66 M | 3.72 M | 3.89 M | - | 3.96 M | 3.55 M | 4.12 M | - | 3.54 M | 3.23 M | 2.16 M |
Interest Expense |
698 K | 640 K | 705 K | - | 836 K | 773 K | 915 K | - | 812 K | 747 K | 680 K | - | 198 K | 142 K | 8 K | - | 59 K | 60 K | 10 K | - | 1 K | - | 125 K | - | 76 K | 84 K | 36 K | - | 79 K | 500 K | 37 K | - | 17 K | 23 K | 26 K | - | 41 K | 64 K | 101 K | - | 127 K | -43 K | -210 K | - | -107 K | -132 K | -61 K | - | -88 K | -89 K | -102 K | - | -111 K | -122 K | -178 K | - | -265 K | -281 K | -15 K |
EBITDA |
- | - | 3.35 M | - | - | - | 4.04 M | - | - | - | 4.59 M | - | 5.6 M | 5.36 M | 4.67 M | - | 5.58 M | 5.09 M | 4.05 M | - | 4.08 M | 2.31 M | 4.04 M | - | 4.9 M | 4.84 M | 4.28 M | - | 4.98 M | 5.45 M | 5.17 M | - | 5.17 M | 5.36 M | 4.89 M | - | 4.39 M | 4.61 M | 4.46 M | - | 4.46 M | 4.27 M | 4.03 M | - | 4.48 M | 4.37 M | 4 M | - | 4.12 M | 4.02 M | 4.04 M | - | 4.45 M | 3.89 M | 4.94 M | - | 4.08 M | 3.59 M | 2.42 M |
Operating Expenses |
2.99 M | 2.4 M | 2.38 M | - | 2.46 M | 2.82 M | 2.88 M | - | 3.39 M | 3.31 M | 3.4 M | - | 3.04 M | 3.09 M | 3.01 M | - | 2.98 M | 3.02 M | 3.06 M | - | 2.91 M | 2.97 M | 2.97 M | - | 3.01 M | 3.02 M | 2.67 M | - | 1.89 M | 1.93 M | 1.95 M | - | 1.82 M | 1.86 M | 1.81 M | - | 1.84 M | 1.94 M | 1.91 M | - | 2.08 M | 2.13 M | 2.24 M | - | 2.19 M | 2.29 M | 2.21 M | - | 2.28 M | 2.33 M | 2.39 M | - | 2.52 M | 2.52 M | 2.62 M | - | 2.98 M | 3.03 M | 1.55 M |
General and Administrative Expenses |
2.83 M | 2.26 M | 2.23 M | - | 2.29 M | 2.56 M | 2.62 M | - | 3.25 M | 3.18 M | 3.26 M | - | 2.93 M | 2.96 M | 2.89 M | - | 2.85 M | 2.89 M | 2.93 M | - | 2.78 M | 2.86 M | 2.84 M | - | 2.88 M | 2.91 M | 2.56 M | - | 1.78 M | 1.81 M | 1.84 M | - | 1.71 M | 1.74 M | 1.69 M | - | 1.7 M | 1.82 M | 1.8 M | - | 1.97 M | 1.99 M | 2.08 M | - | 2.08 M | 2.17 M | 2.08 M | - | 2.16 M | 2.21 M | 2.27 M | - | 2.38 M | 2.37 M | 2.48 M | - | 2.84 M | 2.88 M | 1.45 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Utah Medical Products (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Alcon
ALC
|
$ 76.42 | 0.84 % | $ 40.4 B |  Schweiz |
 |
Ekso Bionics Holdings
EKSO
|
$ 11.38 | 3.58 % | $ 27.6 M | USA |
 |
The Cooper Companies
COO
|
$ 64.84 | 0.65 % | $ 12.9 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 128.0 | 4.62 % | $ 4.1 B | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Repro Med Systems
KRMD
|
$ 4.08 | 3.03 % | $ 188 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Microbot Medical
MBOT
|
$ 2.19 | -0.68 % | $ 100 M |  Israel |
 |
Milestone Scientific
MLSS
|
$ 0.32 | 1.56 % | $ 26.3 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 60.56 | 0.97 % | $ 3.05 B | USA |
 |
electroCore
ECOR
|
$ 6.26 | 1.38 % | $ 53.1 K | USA |
 |
ICU Medical
ICUI
|
$ 123.92 | -0.72 % | $ 3.05 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 26.98 | 0.71 % | $ 4.53 B | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
$ 478.58 | -0.69 % | $ 171 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 123.44 | 1.46 % | $ 5.98 B | USA |
 |
STERIS plc
STE
|
$ 222.53 | 0.35 % | $ 21.9 B | USA |
 |
Masimo Corporation
MASI
|
$ 178.69 | 0.03 % | $ 9.52 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 10.9 | 5.62 % | $ 225 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 136.93 | 0.27 % | $ 6.11 B | USA |
 |
Merit Medical Systems
MMSI
|
$ 68.27 | -0.45 % | $ 4.04 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 23.17 | 0.65 % | $ 1.56 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 303.47 | -0.79 % | $ 21.9 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.95 | 0.29 % | $ 2.38 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.65 | 1.25 % | $ 19.5 M | USA |
 |
Pro-Dex
PDEX
|
$ 51.95 | -0.29 % | $ 171 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 115.0 | 1.37 % | $ 2.6 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 26.41 | 2.88 % | $ 1.31 B | USA |
 |
BioLife Solutions
BLFS
|
$ 21.6 | 1.03 % | $ 995 M | USA |
 |
Stereotaxis
STXS
|
$ 1.95 | 0.78 % | $ 177 M | USA |
 |
Baxter International
BAX
|
$ 18.39 | 1.27 % | $ 9.43 B | USA |
 |
ResMed
RMD
|
$ 221.1 | 0.63 % | $ 32.3 B | USA |
 |
AtriCure
ATRC
|
$ 29.43 | 0.51 % | $ 1.41 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 6.77 | -1.31 % | $ 301 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
$ 11.23 | 1.13 % | $ 459 M | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 152.7 | 0.38 % | $ 43.9 B | USA |
 |
Nephros
NEPH
|
$ 3.03 | 5.4 % | $ 31.5 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.01 | 0.17 % | $ 221 M | USA |
 |
Repligen Corporation
RGEN
|
$ 118.88 | 1.09 % | $ 6.62 M | USA |